Report
Moderna Inc
325 BINNEY STREET
Phone: (617) 714-6500p:617 714-6500 Cambridge, MA  02142  United States Ticker: MRNAMRNA

Modern vaccine has potential for lasting immunity


Moderna announced that participants in phase 1 of the study of their mRNA-1273 vaccine maintained high levels of disease neutralizing antibodies over 119 days of first vaccination.

The study was carried out by the U.S. Institute of Allergies and Infectious Diseases.

"These data reinforce our optimism that the high level of effectiveness recently demonstrated by mRNA-1273 to prevent covid-19 will be lasting," said Tal Zaks, director of Moderna's medical department, as cited by Bloomberg.

It is recalled that the U.S. biotech, which has already asked the U.S. drug regulator for authorization for the use of the vaccine in emergency situations, announced an efficacy of 94.1% in the third phase of clinical trials.

The company reaffirmed tonight its expectation of having about 20 million doses available in the U.S. by the end of this year.

In addition, it expects to have between 100 and 125 million doses available worldwide in the first quarter of 2021 - with 85 to 100 million of these doses in the U.S. and 15 to 25 million outside the country.

On 24 November, European Commission President Ursula von der Leyen announced that she had signed a contract with Moderna to secure up to 160 million doses (which have an estimated unit price of EUR 21) of her covid-19 vaccine. It was brussels' sixth contract in the framework of this pandemic.

Related Businesses
- - Customer
Copyright © 2024 by CreditRiskMonitor.com (Ticker: CRMZ®). All rights reserved.  You are not permitted to use this report or the information contained herein for any purpose not expressly permitted by CreditRiskMonitor.com, Inc. Except as expressly permitted by CreditRiskMonitor.com, Inc., you are not permitted, in whole or in part, to copy, alter, correct, adapt, translate, enhance, lease, sell, sublicense, assign, distribute, publish, otherwise make available to any third party, or prepare derivative works or improvements of this report or any of the information contained therein. You are not permitted to reverse engineer, disassemble, decompile, decode, or adapt the software, algorithms or other processes used to prepare this report, or otherwise attempt to derive or gain access to the source code of same. You agree not to remove, alter, obscure, combine or otherwise change any disclaimers, trademarks, copyrights, other intellectual property rights, proprietary rights, or other symbols, notices, marks, or serial numbers on or relating to any copy of the report or on marketing or other materials that CreditRiskMonitor.com, Inc. may provide to you. You will not use this report in any manner or for any purpose that infringes, misappropriates, or otherwise violates any right of any party, or that violates any applicable law.  
The FRISK® scores, agency ratings, credit limit recommendations and other scores, analysis and commentary are opinions of CreditRiskMonitor.com, Inc. and/or its suppliers, not statements of fact, and should be one of several factors in making credit decisions.  Any reliance you place on the information in this report is strictly at your own risk. Except as expressly provided by CreditRiskMonitor.com, Inc., no warranties or representations of any type, including without limitation of results to be obtained, merchantability or fitness for a particular purpose, are made concerning any part of CreditRiskMonitor.com, Inc.’s service, including without limitation the FRISK® scores.  The information published above has been obtained from sources CreditRiskMonitor considers to be reliable.  CreditRiskMonitor.com, Inc. and its third-party suppliers do not guarantee or validate the accuracy and completeness of the information provided in this report, the underlying information input to create the FRISK® scores, and specifically do not assume responsibility for not reporting any information omitted or withheld.  By using this website, you accept the Terms of Use Agreement. 
Contact Us: 845.230.3000
Fundamental financial data concerning public companies may be provided by Refinitiv (click for restrictions)
Tuesday, April 23, 2024